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Autoimmune reactions involving cytochrome P4502E1 (CYP2E1) are a feature of idiosyncratic liver injury
induced by halogenated hydrocarbons and isoniazid, but are also detectable in about one third of the
patients with advanced alcoholic liver disease (ALD) and chronic hepatitis C (CHC). In these latter the
presence of anti-CYP2E1 auto-antibodies is an independent predictor of extensive necro-inflammation
and fibrosis and worsens the recurrence of hepatitis following liver transplantation, indicating that
CYP2E1-directed autoimmunity can contribute to hepatic injury. The molecular characterization of the
antigens recognized by anti-CYP2E1 auto-antibodies in ALD and CHC has shown that the targeted con-
formational epitopes are located in close proximity on the molecular surface. Furthermore, these epi-
topes can be recognized on CYP2E1 expressed on hepatocyte plasma membranes where they can trigger
antibody-mediated cytotoxicity. This does not exclude that T cell-mediated responses against CYP2E1
might also be involved in causing hepatocyte damage. CYP2E1 structural modifications by reactive
metabolites and molecular mimicry represent important factors in the breaking of self-tolerance against
CYP2E1 in, respectively, ALD and CHC. However, genetic or acquired interferences with the mechanisms
controlling the homeostasis of the immune system are also likely to contribute. More studies are needed
to better characterize the impact of anti-CYP2E1 autoimmunity in liver diseases particularly in relation to
the fact that common metabolic alterations such as obesity and diabetes stimulates hepatic CYP2E1
expression.
& 2014 Published by Elsevier B.V.ContentsCYPs as targets of auto-immunity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Autoimmune reactions targeting CYP2E1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 73
Characterization of antigenic epitopes in CYP2E1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Possible mechanisms of liver injury by anti-CYP2E1 autoantibodies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Mechanisms in the breaking of immune-tolerance toward CYP2E1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
Conflict of interest. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76
References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 76chronic hepatitis C; CTLA-4,
ochrome P450; DC, dendritic
ical; LKM-1, anti-liver kidney
ansplant; Tregs, regulatory T
ce, University “Amedeo Avo-
0, Italy.
).CYPs as targets of auto-immunity
Enzymes are common targets of immune-mediated reactions in
liver autoimmune diseases. In these conditions, the breaking of
self tolerance often involves various cytochrome P450 (CYP) iso-
enzymes [1]. CYPs are a large family of heme-containing proteins
that are involved in the biotransformation of xenobiotics, but are
also responsible for processing endogenous substrates and in the
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homologies various CYPs are classified in families and sub-families
identified by a combination of numbers and letters [2]. The in-
volvement of CYPs as targets in autoimmunity streams from early
reports showing that steroyl-21α hydroxylase (CYP21), cholesterol
side-chain cleavage enzyme (CYP11A) and steroid-17α hydro-
xylase (CYP17) were the major adrenal cortex auto-antigens in
idiopathic Addison's disease [3], while anti-CYP1A1 auto-anti-
bodies are a characteristic of the hepatitis associated with type-1
polyendocrine syndrome [4]. From these observations, subsequent
studies have implicated immunity against hepatic CYPs in idio-
syncratic adverse reactions to drugs and in autoimmune hepatitis.
In particular, antibodies against different CYP isoforms were de-
tected in the case of dihydralazine- (anti-CYP1A2) or tienilic acid-
(anti-CYP2C9) induced hepatitis as well as during hypersensitivity
reactions to the aromatic anti-convulsants (anti-CYP3A) or in
children treated with immunosuppressive drugs (CYP3A4,
CYP2C9) [5–9]. The relevance of these observations in relation to
the pathogenesis of drug-induced hepatitis was supported by the
demonstration of that several functional CYP isoforms are trans-
ported from the Golgi apparatus via the secretory vesicles [10] to
the plasma membrane of hepatocytes, where they and can be
targeted by anti-CYP antibody [11,12].
A further aspect of the involvement of CYP in autoimmune
reactions against the liver concerns anti-liver kidney microsome
type I (LKM-1) antibodies which specifically target CYP2D6 [1] and
are detectable in type II auto-immune hepatitis and in about 10%
of patients with virus C (HCV) hepatitis [13]. Because of their
prevalence, LKM-1 auto-antibodies have been extensively in-
vestigated showing that they recognize few immune-dominant
epitopes formed by specific amino acid sequences located on the
surface of the molecule [14–18]. CYP2D6, as other CYP isoenzymes,
reaches the hepatocyte plasma membranes where can be targeted
by circulating LKM-1 antibodies [19]. The clinical relevance of anti-
CYP2D6 auto-reactivity is further supported by the detection of
auto-reactive cytotoxic T-lymphocytes in patients with type-II
autoimmune hepatitis and high titers of anti-CYP2D6 IgG [20,21].
Moreover, mice infection with CYP2D6-expressing Ad5 adenovirus
leads to the production of anti-CYP2D6 IgG that cause immune-
mediated liver injury by recognizing the same epitopes targeted
by human auto-antibodies [22]. It is also noteworthy that beside
CYP2D6, hepatitis C patients show auto-antibodies against other
members of the CYP2 family, particularly CYP2A6 [23,24].Autoimmune reactions targeting CYP2E1
Among the cytochrome P-450 family members, the isoenzyme
2E1 (CYP2E1) has been extensively investigated as it is a key en-
zyme in the metabolic activation of a variety of xenobiotics and
carcinogens, including nitrosamines, benzene, vinyl chloride and
halogenated solvents, and significantly contributes to the meta-
bolism of ethanol to acetaldehyde [25]. As others CYPs, the 2E1
isoenzyme is readily inducible by the exposure to xenobiotics and
alcohol consumption, but also by ketone bodies and hypoxia [25].
Furthermore, CYP2E1 has a high NADPH oxidase activity that leads
to the generation of reactive oxygen species (ROS) and sig-
nificantly contributes to the induction of oxidative stress in many
pathological conditions [25]. Within the liver, CYP2E1 is mainly
expressed in the endoplasmic reticulum of centrilobular hepato-
cytes, but two CYP2E1 variants accounting for 30–40% of the mi-
crosomal enzyme activity are also localized in the mitochondrial
matrix (mtCYP2E1s) [25]. Moreover, a small CYP2E1 fraction
(about 10% or the microsomal content) is also expressed on the
outer layer of the hepatocyte plasma membranes [26]. Plasma
membrane CYP2E1 is catalytically active [27], but this latterlocalization is particularly important in relation to auto-immune
reactions.
The involvement of CYP2E1 in liver autoimmunity has emerged
from studies by Bourdi and co-workers [28] and Eliasson and
Kenna [29] who reported that about 70% of the patients suffering
from hepatitis induced by the halogenated anesthetic halothane
develop auto-antibodies specifically targeting CYP2E1. These auto-
antibodies were identified as IgG isotype 4 [30]. Anti-CYP2E1 IgG
were also detected in anesthesiologists exposed to halogenated
hydrocarbon anesthetic gases [31], but not in other workers pro-
fessionally exposed to similar gases used in refrigeration industry
[32], in spite these latter may cause liver damage [33]. More re-
cently, CYP2E1 has been recognized together with CYP3A4 and
CYP2C9 as self-antigen in autoimmune reactions developing in
subjects with idiosyncratic liver injury following isoniazid-based
treatment for tuberculosis [34].
As mentioned above, CYP2E1 plays an important role in hepatic
alcohol metabolism. During CYP2E1-mediated ethanol oxidation
ethanol it self is converted to a free radical intermediate, known as
hydroxyethyl free radicals (HER), that by reacting with CYP2E1
generate immunogenic adducts [35]. These anti-HER antibodies
are detectable in the sera of either chronically ethanol-fed rats or
patients with alcoholic liver disease (ALD) where they strictly
correlate with CYP2E1 activity [36,37]. Moreover, human anti-HER
IgG activate antibody-dependent cell-mediated cytotoxicity by
selectively recognizing HER-modified CYP2E1 on the plasma
membranes of ethanol-treated hepatocytes [38]. By extending
these observations, Lytton and co-workers have reported that
chronic intragastric alcohol-fed rats develop IgG directed towards
CYP2E1 and CYP3A4 and that similar antibodies were also evident
in the sera of alcohol abusers [39]. Interestingly, rats anti-CYP2E1
auto-reactivity correlates with the extent of hepatic injury [39]. In
subsequent studies using a larger cohort of patients we have
confirmed that high titers of anti-CYP2E1 auto-antibodies are
present in about 40% of the subjects with advanced ALD and 11% of
the heavy drinkers with fatty liver only [40]. In the former the
presence of anti-CYP2E1 IgG correlates with the extent of lym-
phocyte infiltration and the number of apoptotic hepatocytes in
liver biopsies [41], suggesting a possible contribution of auto-im-
mune mechanisms in the pathogenesis of alcohol liver injury. The
presence of anti-CYP2E1 immunity in ALD is not surprising, as
these subjects frequently have signs of auto- and allo-immune
reactions that are associated with the stimulation of lobular in-
flammation [42,43]. In particular, ALD patients show circulating
anti-phospholipid auto-antibodies as well as IgG targeting pro-
teins modified by the reaction with acetaldehyde, acetaldehyde/
malondialdehyde (MAA) conjugates and lipid peroxidation end-
products [44–48].
An other liver disease often associated with the presence of
autoimmune responses involving CYP2E1 is chronic hepatitis C
(CHC). Extrahepatic manifestations of autoimmunity are a com-
mon feature of CHC along with the presence of non-organ-specific
auto-antibodies [14]. Furthermore, as mentioned above anti-
CYP2D6 LKM-1 auto-antibodies are detectable in about 10% of CHC
patients [14]. Using immuno-enzymatic tests we have observed
that 38–40% of CHC patients have anti-CYP2E1 IgG which are
unrelated to LKM-1 antibodies and do not cross-react with
CYP2D6 [49,50]. The presence of these auto-antibodies is in-
dependent from circulating gamma-globulin levels and the viral
genotype, indicating that they represent a general response to HCV
infection [49,50]. It is interesting to note that, in spite both alcohol
and HCV infection promote the development of anti-CYP2E1 au-
toimmunity, in our hands alcohol consumption by CHC patients
did not increase the prevalence of anti-CYP2E1 auto-antibodies
[49,50], suggesting that the breaking of self-tolerance promoted by
alcohol and HCV infection are a rather independent and do not
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auto-antibodies in CHC are associated with a 11 fold increase in
the prevalence of severe necro-inflammation (grading Z4 ac-
cording to Ishack's criteria) and 4 fold increased risk of fibrosis.
Moreover, multivariate analysis indicates anti-CYP2E1 IgG as an in-
dependent predictors of severe necro-inflammation in hepatitis C
[49,50]. A further aspect of the involvement of anti-CYP2E1 auto-re-
activity in CHC concerns the outcomes of the disease following liver
transplantation. Now days end-stage CHC is becoming the main in-
dication for orthotopic liver transplant (OLT) in Europe and United
States. However, the recurrence of HCV infection in the transplanted
organ is universal and the disease in OLT recipients follows a more
aggressive course [51]. In this context, the development of auto-
immune reactions after OLT is reported with rising frequency [52]. By
investigating OLT recipients before and twelve months after trans-
plantation we have observed that the prevalence of anti-CYP2E1 auto-
antibodies in these patients is not appreciably modified by the liver
transplant. However, the subjects who have elevated anti-CYP2E1 IgG
before and maintained it after OLT have significantly higher incidence
of recurrent hepatitis with severe necro-inflammation and fibrosis
than those persistently negative or showing anti-CYP2E1 reactivity
only before or after the transplant [53]. Moreover, the subjects per-
sistently anti-CYP2E1-positive are at high risk of developing severe
liver damage one year after OLT [53], indicating that autoimmune
reactions involving CYP2E1 might contribute to hepatic injury in
transplanted patients with recurrent hepatitis C.Characterization of antigenic epitopes in CYP2E1
The analysis aimed to characterize the epitopes recognized by
anti-CYP2E1 IgG associated with alcohol abuse, drug-inducedFig. 1. Tri-dimensional simulated structure of CYP2E1 showing the localization of the con
with alcoholic liver disease or halothane-induced hepatitis (panels A, B) or chronic hepati
is evidenced in orange and specific amino acids are stained in purple. (Panel B) The ep
interpretation of the references to color in this figure legend, the reader is referred to thepatotoxicity and HCV infection have revealed that, in-
dependently from the etiology, these auto-antibodies are mainly
unreactive toward the unfolded molecule, indicating a prevalent
recognition of conformational antigens [54,55]. This make difficult
to identify the specific epitopes as they can not be investigated by
their cross-reaction with short peptides reproducing the protein
sequence. To overcome such a difficulty we have used a metho-
dology based on the combination of computer simulation and the
analysis of the whole molecule antigenic properties following
targeted single amino acid substitutions which do not alter
CYP2E1 correct folding [54]. By this approach we have shown that
anti-CYP2E1 IgG from patients with halothane hepatitis or ALD
preferentially recognized two distinct epitopes on the CYP2E1
surface corresponding to the G-helix (Lys243 -Lys251) and an area
(Lys324 -Glu421) formed by juxtaposition of the J′ and K″ helices,
respectively (Fig. 1) [54]. In a similar manner anti-CYP2E1 anti-
bodies associated with CHC target an area comprised between
Lys324 and Glu346 at the juxtaposition of the J and J′ helices (Fig. 1)
that partially overlaps with one the epitopes recognized by anti-
bodies from ALD and halothane-induced hepatitis subjects [55]. This
suggest the possible presence of antigenic hot-spots of CYP2E1 mo-
lecular structure. In the same vein, sequence alignments demonstrate
that the CYP2E1324–346 epitope is has an amino acid sequence close
to the peptides CYP2D6316–327 and CYP2D6321–379 that are among the
most frequent targets of anti-CYP2D6 LKM-1 antibodies [17,56]. In-
terestingly, the J, K and L helices are also binding sites of anti-CYP2C9
and anti-CYP3A4 conformational antibodies associated with tienilic
acid-induced autoimmune hepatitis and hypersensitivity reactions to
aromatic anti-convulsing drugs, respectively [7,9]. These analogies
are not surprising considering that CYP2 and CYP3 families have a
high sequence homology and indicate that CYP auto-antigens are
preferentially located in defined and rather conserved structures of
the molecule.formational epitopes recognized by anti-CYP2E1 IgG present in the sera of patients
tis C (panel C). (Panels A, C) The area formed by the juxtaposition of J′ and K″ helices
itope in the G helix comprised between Lys324 and Lys251 is shown in orange. (For
he web version of this article.)
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autoantibodies
As mentioned above, a small fraction of CYP2E1 is located on
the outer layer of hepatocyte the plasma membranes [26,27].
Structural simulations based on CYP2E1 interaction with mem-
brane lipids indicate that the conformational epitopes identified in
G helix and in the area comprising the J–L helices are located on
the outer portion of the molecule and are well accessible to the
antibody binding [54]. In line with this, we have observed that
anti-CYP2E1 auto-antibodies present in CHC [49] as well as those
associated with ALD or halothane-induced hepatitis [29] bind to
hepatocytes by recognizing plasma membrane CYP2E1. Thus, as in
the case of LKM-1 antibodies [19], the binding of anti-CYP2E1 IgG
to conformational epitopes on G and J–L helices has the capability
to trigger antibody-mediated cytotoxicity, thus justifying the
clinical association between anti-CYP2E1 reactivity and the se-
verity of liver injury. Supporting this view we have observed that
HER-modified CYP2E1 can mediate cytotoxic reactions by anti-
HER antibodies from ALD patients [38]. This does not exclude that,
as observed for anti-CYP2D6 auto-reactivity [20,21], T cell-medi-
ated responses against CYP2E1 might also be involved in causing
hepatocyte damage.Mechanisms in the breaking of immune-tolerance toward
CYP2E1
So far, the mechanisms leading to the breaking of self-tolerance
toward hepatic CYP2E1 are still incompletely characterized. The
liver is recognized to have unique immunological properties that
modulate systemic tolerance to antigens from the portal circula-
tion [57,58]. Under physiological conditions, Kupffer cells respond
to low concentrations of bacterial products by producing inter-
leukin-10 (IL-10) and low levels of pro-inflammatory mediators
(TNF-α, ROS and prostanoids) that down-modulate the antigen
presentation by dendritic and endothelial cells, thus suppressing
T-cell activation [58]. Such an effect is lost following liver injury
because of macrophage and dendritic cell (DC) activation in re-
sponse to damage associated molecular patterns (PAMPs) [57].
Classically, B-cell activation, differentiation and proliferation occur
in secondary lymphoid organs or in so-called “ectopic” germinal
centers of non-lymphoid organs. In injured livers intra-portal
lymphoid follicles acquire the features of active germinal centers
[57], making possible the presentation of hepatocyte-derived an-
tigens to B- and CD4þ T-lymphocytes as well as B-cell maturation
to antibody producing plasma cells. Moreover, DCs can also cross-
prime naïve CD8þ T-lymphocytes promoting cell-mediated
responses. Beside DC, antigen presentation might also involve
hepatic stellate cells [59] and possibly hepatocytes themselves, as
pro-inflammatory cytokines have been shown to induce the
hepatocyte expression of class II major histocompatibility complex
(MHC) and co-stimulatory CD80 (B7.1) molecules [60]. Although
during chronic liver injury CYP released from damaged hepato-
cytes might be a trigger for the breaking of self-tolerance, it should
be noted that anti-CYP self-reactivity associated to CHC, alcohol
abuse or adverse drug reactions is highly specific to individual
CYPs [7–10] and there is no cross-reactivity between anti-CYP2E1
and anti-CYP2D6 antibodies [54,55] in HCV-infected patients. This
indicates that additional and more specific mechanisms are likely
involved.
Early studies have postulated that during drug-induced hepa-
titis the binding of reactive metabolites to CYPs would be able to
promote immune responses against the drug-derived epitope
(s) favouring at the same time the activation of normally quiescent
auto-reactive lymphocytes recognizing native CYP molecules [61].Although such a hypothesis has not been definitively proved, it is
interesting to note that antibodies against CYP2E1 modified by the
binding of drug-derived metabolites often accompany the pre-
sence of anti-CYP2E1 auto-antibodies in halothane and isoniazid
idiosyncratic hepatitis [29,34] as well as in ALD [40]. In particular,
we have observed that ALD patients with anti-HER antibodies
have a 4 fold increased risk of developing anti-CYP2E1 auto-re-
activity as compared to patients without anti-HER IgG [40], in-
dicating that CYP2E1 structural modifications induced by HER are
critical for the breaking of self-tolerance. This is consistent with
the observation that small molecular difference are needed for the
breaking of T-cells tolerance versus CYP2D6 in mice developing
autoimmune hepatitis following infection with adenovirus
expressing human CYP2D6 [62]. Furthermore, structural mod-
ifications of the pyruvate dehydrogenase complex consequent to
biotinylation are required for the development auto-reactive
B-cells and T-cells in an experimental model of biliary cirrhosis
[63]. In this contest, genetic polymorphisms that influence the
capacity of CYPs to generate reactive metabolites or that affect
drug metabolite detoxification by phase II enzymes might likely
influence inter-individual variability in the development of anti-
CYP auto-reactivity [64]. However, in spite many genetic poly-
morphisms have been detected in CYP2E1 [65], at the moment no
data has implicated their influence in the susceptibility to auto-
immune responses.
Current researches on the mechanisms by which HCV infection
promotes the onset of autoimmune reactions have focused on the
peculiar ability of HCV to cause molecular mimicry [1,14].
Molecular mimicry defines the possibility that antigens from
microorganisms can activate T-lymphocytes cross-reacting with
self-antigens that share similar linear or conformational structures
[66]. By now mimicry mechanisms involving viral proteins are
recognized to play a key role in the pathogenesis of several human
autoimmune diseases [66]. In the case of anti-CYP auto-reactivity,
mimicry between HCV proteins E1, NS3, NS5a and NS5b and
CYP2D6 accounts for the development of LKM-1 auto-antibodies
[15,18,67] and T-cells antigens in CYP2D6, CYP2A6 and CYP2A7
[13,68]. Moreover, cross-reactivity between CYP2D6 and Cytome-
galovirus and Herpes Simplex virus proteins has also been re-
ported [16,18]. We have observed that the conformational epitopes
in CYP2E1324–346 that are recognized by CHC-associated
anti-CYP2E1 IgG have good sequence homology with two short
peptides (NS5b438–449 and NS5b456–465) well conserved in NS5b
RNA-dependent-DNA polymerase of most of HCV genotypes [55].
Furthermore, molecular imaging shows similarities in the tri-di-
mensional structure of these peptides and those of the epitopes in
CYP2E1 molecule [55]. Accordingly, recombinant NS5b438–449 and
NS5b456–465 peptides cross-react with CHC sera containing con-
formational anti-CYP2E1 IgG, while mice immunized with either
the two viral peptides develop antibodies targeting human
CYP2E1 [55]. Altogether, these data indicate molecular mimicry
with HCV-NS5b a trigger for the development of auto-reactivity
toward CYP2E1 in CHC. This might explain why the prevalence of
anti-CYP2E1 auto-antibodies is unrelated to alcohol consumptions
despite alcohol abuse is itself a trigger of autoimmune responses.
More in general, mimicry mechanisms can be seen as a common
mechanism in the breaking of self-tolerance toward CYPs in HCV
infected patients.
Although CYP2E1 modifications by reactive metabolites and
molecular mimicry can facilitate the selection of B- and T-cells
with specificity toward CYP2E1 epitopes, additional factors may
influence the large inter-individual variability that characterizes
the presence of anti-CYP2E1 auto-reactivity in liver diseases. In
this respect, the activity of regulatory T (Treg) cells is known to
play an important role in the maintenance of immune homeostasis
and in the prevention of autoimmune diseases [69,70]. In the liver,
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tributor in the development of autoimmune hepatitis [71]. Among
the mechanisms by which Tregs regulate immune functions a key
role is played by cytotoxic T lymphocyte associated antigen-4
(CTLA-4) [72]. CTLA-4 is membrane protein that act as an in-
hibitory signal to T cells by competing with CD28 for interacting
with CD80 (B7.1) and CD86 (B7.2) [73,74]. By this mechanism
CTLA-4 interferes with important co-stimulatory signals essential
for T-cell activation [73,74]. The immune-suppressor function of
CTLA-4 is confirmed by observations that CD4þ and CD8þ T- and
of B-cell clones rapidly expand in CTLA-4 knockout mice leading to
lethal auto-reactive diseases [75]. In vitro data have shown that a
human genetic polymorphisms involving a A-G base exchange at
position 49 in exon 1 of the CTLA-4 gene is associated with a di-
minution of the normal inhibitory influence on T cell responses
[73,74]. Moreover, primary biliary cirrhosis, type I auto-immune
hepatitis, Graves' disease and type 1 diabetes mellitus have all
been linked to the presence of such CTLA-4 polymorphisms
[73,74]. We have observed that ALD patients have an increased
prevalence CTLA-4 49 A/G substitution than healthy subjects.
Moreover, in heavy drinkers the presence of the CTLA-4G allele
increases by about four folds the risk of developing anti-CYP2E1
IgG, without influencing the prevalence of antibodies towards
HER-antigens [40]. Interestingly, ALD patients having the combi-
nation both anti-HER IgG and the mutant CTLA-4 G allele have 23-
fold higher risk of anti-CYP2E1 auto-reactivity than the subjects
negative for both these factors [40]. Although ALD patients have
also an increased prevalence of genetic polymorphisms (627C-A
and 1.117G-A) affecting IL-10 secretion by Tregs and macro-
phages, this does not influence the prevalence of anti-CYP2E1 IgG
[40]. Thus, the antigenic stimulation by HER-modified CYP2E1
combined with an impaired control of T cell proliferation due to
CTLA-4 mutation appears to specifically increase the probability to
develop anti-CYP2E1 auto-reactivity. Altogether, these observa-
tions indicate that the breaking of self-tolerance toward CYPs is a
multi-factorial event likely requiring structural modifications of
the target molecule or molecular mimicry along with genetic or
acquired interferences with the mechanisms controlling the
homeostasis of the immune system.Conclusions
Autoimmune reactions involving CYP2E1 play an important
role in idiosyncratic liver injury induced by halogenated hydro-
carbons and isoniazid, but are also detectable in about one third of
the patients with advanced ALD or CHC. In these latter the pre-
sence of anti-CYP2E1 auto-antibodies is an independent predictor
for extensive necro-inflammation and fibrosis. However, more
studies are needed to better characterize the impact of anti-
CYP2E1 autoimmunity in liver diseases particularly in relation to
type II autoimmune hepatitis which is characterized by anti-CYP
auto-reactivity [76] and nonalcoholic steatohepatitis (NASH), as in
this later, insulin resistance associated to obesity stimulates he-
patic CYP2E1 induction [77,78].Conflict of interest
The authors have no conflict of interest.References
[1] D.P. Bogdanos, G.N. Dalekos, Enzymes as target antigens of liver-specific au-
toimmunity: the case of cytochrome P450s, Current Medicinal Chemistry 15(22) (2008) 2285–2292. http://dx.doi.org/10.2174/092986708785747508
18781950.
[2] M.J. Coon, Cytochrome P450: nature's most versatile biological catalyst, An-
nual Review of Pharmacology and Toxicology 45 (2005) 1–25. http://dx.doi.
org/10.1146/annurev.pharmtox.45.120403.100030 15832443.
[3] C. Betterle, Autoimmune adrenal insufficiency and autoimmune polyendocrine
syndromes: autoantibodies, autoantigens, and their applicability in diagnosis
and disease prediction, Endocrine Reviews 23 (3) (2002) 327–354. http://dx.
doi.org/10.1210/edrv.23.3.0466 12050123.
[4] T.O. Lankisch, E. Jaeckel, C.P. Strassburg, The autoimmune polyendocrinopathy-
candidiasis-ectodermal dystrophy or autoimmune polyglandular syndrome
type 1, Seminars in Liver Disease 29 (2009) 307–314. http://dx.doi.org/
10.1055/s-0029-1233535 19676003.
[5] M. Bourdi, D. Larrey, J. Nataf, J. Bernuau, D. Pessayre, M. Iwasaki, F.
P. Guengerich, P.H. Beaune, Anti-liver endoplasmic reticulum autoantibodies
are directed against human cytochrome P-450IA2. A specific marker of dihy-
dralazine-induced hepatitis, Journal of Clinical Investigation 85 (6) (1990)
1967–1973. http://dx.doi.org/10.1172/JCI114660 2347920.
[6] P. Beaune, D. Pessayre, P. Dansette, D. Mansuy, M. Manns, Autoantibodies
against cytochromes P450: role in human diseases, Advances in Pharmacology
30 (1994) 199–245. http://dx.doi.org/10.1016/S1054-3589(08)60175-1
7833293.
[7] J.S. Leeder, A. Gaedigk, X. Lu, V.A. Cook, Epitope mapping studies with human
anti-cytochrome P450 3A antibodies, Molecular Pharmacology 49 (2) (1996)
234–243 8632755.
[8] C. Belloc, A. Gauffre, C. André, P.H. Beaune, Epitope mapping of human CYP1A2
in dihydralazine-induced autoimmune hepatitis, Pharmacogenetics 7 (3)
(1997) 181–186. http://dx.doi.org/10.1097/00008571-199706000-00002
9241657.
[9] S. Lecoeur, C. André, P.H. Beaune, Tienilic acid-induced autoimmune hepatitis:
anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site
conformational epitope on cytochrome P4502C9, Molecular Pharmacology 50
(2) (1996) 326–333 8700140.
[10] E.P. Neve, E. Eliasson, M.A. Pronzato, E. Albano, U. Marinari, M. Ingelman-
Sundberg, Enzyme-specific transport of rat liver cytochrome P450 to the Golgi
apparatus, Archives of Biochemistry and Biophysics 333 (2) (1996) 459–465.
http://dx.doi.org/10.1006/abbi.1996.0415 8809087.
[11] J. Loeper, V. Descatoire, M. Maurice, P. Beaune, G. Feldmann, D. Larrey,
D. Pessayre, Presence of functional cytochrome P-450 on isolated rat hepato-
cyte plasma membrane, Hepatology 11 (5) (1990) 850–858. http://dx.doi.org/
10.1002/hep.1840110521 2112112.
[12] J. Loeper, V. Descatoire, M. Maurice, P. Beaune, J. Belghiti, D. Houssin, F. Ballet,
G. Feldmann, F.P. Guengerich, D. Pessayre, Cytochromes P-450 in human he-
patocyte plasma membrane: recognition by several autoantibodies, Gastro-
enterology 104 (1) (1993) 203–216 7678237.
[13] D. Bogdanos, G. Mieli-Vergani, D. Vergani, Autoantibodies and their antigens
in autoimmune hepatitis, Seminars in Liver Disease 29 (03) (2009) 241–253.
http://dx.doi.org/10.1055/s-0029-1233533.
[14] S. Ferri, L. Muratori, M. Lenzi, A. Granito, F. Bianchi, D. Vergani, HCV and au-
toimmunity, Current Pharmaceutical Design 14 (17) (2008) 1678–1685. http:
//dx.doi.org/10.2174/138161208784746824.
[15] M.P. Manns, K.J. Griffin, K.F. Sullivan, E.F. Johnson, LKM-1 autoantibodies re-
cognize a short linear sequence in P450IID6, a cytochrome P-450 mono-
oxygenase, Journal of Clinical Investigation 88 (4) (1991) 1370–1378. http://dx.
doi.org/10.1172/JCI115443 1717511.
[16] A.M. Yamamoto, D. Cresteil, J.C. Homberg, F. Alvarez, Characterization of anti-
liver-kidney microsome antibody (anti-LKM1) from hepatitis C virus-positive
and -negative sera, Gastroenterology 104 (6) (1993) 1762–1767 7684716.
[17] T. Sugimura, P. Obermayer-Straub, A. Kayser, S. Braun, S. Loges, B. Alex,
B. Lüttig, E.F. Johnson, M.P. Manns, C.P. Strassburg, A major CYP2D6 auto-
epitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-
dimensional structure homologous to other cytochrome P450 autoantigens,
Autoimmunity 35 (8) (2002) 501–513. http://dx.doi.org/10.1080/
0891693021000069556 12765476.
[18] N. Kerkar, K. Choudhuri, Y. Ma, A. Mahmoud, D.P. Bogdanos, L. Muratori,
F. Bianchi, R. Williams, G. Mieli-Vergani, D. Vergani, Cytochrome
P4502D6193–212: a new immunodominant epitope and target of virus/self
cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver
disease, Journal of Immunology 170 (3) (2003) 1481–1489. http://dx.doi.org/
10.4049/jimmunol.170.3.1481 12538711.
[19] L. Muratori, M. Parola, A. Ripalti, G. Robino, P. Muratori, G. Bellomo, R. Carini,
M. Lenzi, M.P. Landini, E. Albano, F.B. Bianchi, Liver/kidney microsomal anti-
body type 1 targets CYP2D6 on hepatocyte plasma membrane, Gut 46 (4)
(2000) 553–561. http://dx.doi.org/10.1136/gut.46.4.553 10716687.
[20] Y. Ma, D.P. Bogdanos, M.J. Hussain, J. Underhill, S. Bansal, M.S. Longhi,
P. Cheeseman, G. Mieli-Vergani, D. Vergani, Polyclonal T-cell responses to
cytochrome P450IID6 are associated with disease activity in autoimmune
hepatitis type 2, Gastroenterology 130 (3) (2006) 868–882. http://dx.doi.org/
10.1053/j.gastro.2005.12.020 16530525.
[21] M.S. Longhi, M.J. Hussain, D.P. Bogdanos, A. Quaglia, G. Mieli-Vergani, Y. Ma,
D. Vergani, Cytochrome P450IID6-specific CD8 T cell immune responses mir-
ror disease activity in autoimmune hepatitis type 2, Hepatology 46 (2) (2007)
472–484. http://dx.doi.org/10.1002/hep.21658 17559153.
[22] P. Lapierre, I. Djilali-Saiah, S. Vitozzi, F. Alvarez, A murine model of type
2 autoimmune hepatitis: Xenoimmunization with human antigens, Hepatol-
ogy 39 (4) (2004) 1066–1074. http://dx.doi.org/10.1002/hep.20109.
S. Sutti et al. / Redox Biology 3 (2014) 72–78 77[23] G.N. Dalekos, P. Obermayer-Straub, M. Bartels, T. Maeda, A. Kayser, S. Braun,
S. Loges, E. Schmidt, M.E. Gershwin, M.P. Manns, Cytochrome P450 2A6: a new
hepatic autoantigen in patients with chronic hepatitis C virus infection,
Journal of Hepatology 39 (5) (2003) 800–806. http://dx.doi.org/10.1016/
S0168-8278(03)00356-8 14568264.
[24] H. Miyakawa, E. Kitazawa, K. Kikuchi, H. Fujikawa, N. Kawaguchi, K. Abe,
M. Matsushita, H. Matsushima, T. Igarashi, R.W. Hankins, M. Kako, Im-
munoreactivity to various human cytochrome P450 proteins of sera from
patients with autoimmune hepatitis, chronic hepatitis B, and chronic hepatitis
C, Autoimmunity 33 (1) (2000) 23–32. http://dx.doi.org/10.3109/
08916930108994106 11204250.
[25] Y. Lu, A.I. Cederbaum, CYP2E1 and oxidative liver injury by alcohol, Free Ra-
dical Biology and Medicine 44 (5) (2008) 723–738. http://dx.doi.org/10.1016/j.
freeradbiomed.2007.11.004 18078827.
[26] E.P. Neve, M. Ingelman-Sundberg, Molecular basis for the transport of cyto-
chrome P450 2E1 to the plasma membrane, Journal of Biological Chemistry
275 (22) (2000) 17130–17135. http://dx.doi.org/10.1074/jbc.M000957200
10747972.
[27] D.F. Wu, A.I. Cederbaum, Presence of functionally active cytochrome P-450IIE1
in plasma membrane of rat hepatocytes, Hepatology 15 (1992) 515–524.
[28] M. Bourdi, W. Chen, R.M. Peter, J.L. Martin, J.T. Buters, S.D. Nelson, L.R. Pohl,
Human cytochrome P450 2E1 is a major autoantigen associated with ha-
lothane hepatitis, Chemical Research in Toxicology 9 (7) (1996) 1159–1166.
http://dx.doi.org/10.1021/tx960083q 8902272.
[29] E. Eliasson, J.G. Kenna, Cytochrome P450 2E1 is a cell surface autoantigen in
halothane hepatitis, Molecular Pharmacology 50 (3) (1996) 573–582 8794896.
[30] D.B. Njoko, J.L. Mellerson, M.V. Talor, D.R. Kerr, N.R. Faraday, I. Outshoor,
N.R. Rose, Role of CYP2E1 immunoglobulin G4 subclass antibodies and com-
plement in the pathogenesis of idiosyncratic drug-induced hepatitis, Clinical
and Vaccine Immunology 13 (2006) 258–265.
[31] D.B. Njoku, R.S. Greenberg, M. Bourdi, C.B. Borkowf, E.M. Dake, J.L. Martin,
L.R. Pohl, Autoantibodies associated with volatile anesthetic hepatitis found in
the sera of a large cohort of pediatric anesthesiologists, Anesthesia & Analgesia
94 (2) (2002) 243–249. http://dx.doi.org/10.1213/00000539-200202000-
00003 11812677.
[32] S. Gunnare, M. Vidali, L. Lillienberg, L. Ernstgård, B. Sjögren, M. Hagberg,
E. Albano, G. Johanson, Non-positive autoimmune responses against CYP2E1
in refrigeration mechanics exposed to halogenated hydrocarbons, Science of
the Total Environment 383 (1–3) (2007) 90–97. http://dx.doi.org/10.1016/j.
scitotenv.2007.05.005 17582468.
[33] P. Hoet, M.L. Graf, M. Bourdi, L.R. Pohl, P.H. Duray, W. Chen, R.M. Peter,
S.D. Nelson, Epidemic of liver disease caused by hydrochlorofluorocarbons
used as ozone-sparing substitutes of chlorofluoro carbons, Lancet 350 (9077)
(1997) 556–559. http://dx.doi.org/10.1016/S0140-6736(97)03094-8 9284778.
[34] I.G. Metushi, C. Sanders, Acute Liver Study GroupW.M. Lee, J. Uetrecht, De-
tection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with
isoniazid-induced liver failure, Hepatology 59 (3) (2014) 1084–1093. http://dx.
doi.org/10.1002/hep.26564 23775837.
[35] E. Albano, S.W. French, M. Ingelman-Sundberg, Hydroxyethyl radicals in
ethanol hepatotoxicity, Frontiers in Bioscience 4 (1999) D533–D540. http://dx.
doi.org/10.2741/Albano 10369806.
[36] E. Albano, P. Clot, M. Morimoto, A. Tomasi, M. Ingelman-Sundberg, S.
W. French, Role of cytochrome P4502E1-dependent formation of hydroxyethyl
free radical in the development of liver damage in rats intragastrically fed
with ethanol, Hepatology 23 (1) (1996) 155–163. http://dx.doi.org/10.1002/
hep.510230121 8550035.
[37] P. Clot, E. Albano, E. Eliasson, M. Tabone, S. Aricò, Y. Israel, C. Moncada,
M. Ingelman-Sundberg, Cytochrome P4502E1 hydroxyethyl radical adducts as
the major antigen in autoantibody formation among alcoholics, Gastro-
enterology 111 (1) (1996) 206–216. http://dx.doi.org/10.1053/gast.1996.v111.
pm8698201 8698201.
[38] P. Clot, M. Parola, G. Bellomo, U. Dianzani, R. Carini, M. Tabone, S. Aricò,
M. Ingelman-Sundberg, E. Albano, Plasma membrane hydroxyethyl radical
adducts cause antibody-dependent cytotoxicity in rat hepatocytes exposed to
alcohol, Gastroenterology 113 (1) (1997) 265–276. http://dx.doi.org/10.1016/
S0016-5085(97)70104-5 9207287.
[39] S.D. Lytton, U. Berg, A. Nemeth, M. Ingelman-Sundberg, Autoantibodies
against cytochrome P450s in sera of children treated with im-
munosuppressive drugs, Clinical & Experimental Immunology 127 (2) (2002)
293–302. http://dx.doi.org/10.1046/j.1365-2249.2002.01754.x 11876753.
[40] M. Vidali, S.F. Stewart, R. Rolla, A.K. Daly, Y. Chen, E. Mottaran, D.E. Jones,
J.B. Leathart, C.P. Day, E. Albano, Genetic and epigenetic factors in autoimmune
reactions toward cytochrome P4502E1 in alcoholic liver disease, Hepatology
37 (2) (2003) 410–419. http://dx.doi.org/10.1053/jhep.2003.50049 12540792.
[41] S.F. Stewart, D.E.J. Jones, M. Vidali, B. Haugk, A.D. Brunt, E. Albano, C.P. Day,
Correlation between anti-CYP2E1 titre and lymphocyte infiltration in ALD- an
autoimmune disease in some patients, Journal of Hepatology 40 (Suppl. 1)
(2004) 176.
[42] I.G. McFarlane, Autoantibodies in alcoholic liver disease, Addiction Biology 5
(2) (2000) 141–151. http://dx.doi.org/10.1080/13556210050003720 20575828.
[43] M. Vidali, S.F. Stewart, E. Albano, Interplay between oxidative stress and im-
munity in the progression of alcohol-mediated liver injury, Trends in Mole-
cular Medicine 14 (2) (2008) 63–71. http://dx.doi.org/10.1016/j.
molmed.2007.12.005 18222109.
[44] D. Vay, C. Rigamonti, M. Vidali, E. Mottaran, E. Alchera, G. Occhino, M. Sartori,
E. Albano, Anti-phospholipid antibodies associated with alcoholic liver diseasetarget oxidized phosphatidylserine on apoptotic cell plasma membranes,
Journal of Hepatology 44 (1) (2006) 183–189. http://dx.doi.org/10.1016/j.
jhep.2005.06.010 16143424.
[45] G.M. Thiele, T.L. Freeman, L.W. Klassen, Immunologic mechanisms of alcoholic
liver injury, Seminars in Liver Disease 24 (3) (2004) 273–287. http://dx.doi.
org/10.1055/s-2004-832940 15349805.
[46] R. Rolla, D. Vay, E. Mottaran, M. Parodi, N. Traverso, S. Aricò, M. Sartori,
G. Bellomo, L.W. Klassen, G.M. Thiele, D.J. Tuma, E. Albano, Detection of cir-
culating antibodies against malondialdehyde-acetaldehyde adducts in pa-
tients with alcohol-induced liver disease, Hepatology 31 (4) (2000) 878–884.
http://dx.doi.org/10.1053/he.2000.5373 10733543.
[47] E. Mottaran, S.F. Stewart, R. Rolla, D. Vay, V. Cipriani, M. Moretti, M. Vidali,
M. Sartori, C. Rigamonti, C.P. Day, E. Albano, Lipid peroxidation contributes to
immune reactions associated with alcoholic liver disease, Free Radical Biology
and Medicine 32 (1) (2002) 38–45. http://dx.doi.org/10.1016/S0891-5849(01)
00757-2 11755315.
[48] S.F. Stewart, M. Vidali, C.P. Day, E. Albano, D.E. Jones, Oxidative stress as a
trigger for cellular immune responses in patients with alcoholic liver disease,
Hepatology 39 (1) (2004) 197–203. http://dx.doi.org/10.1002/hep.20021
14752838.
[49] M. Vidali, G. Occhino, A. Ivaldi, R. Serino, S. Moia, E. Alchera, R. Carini,
C. Rigamonti, M. Sartori, E. Albano, Detection of auto-antibodies against cy-
tochrome P4502E1 (CYP2E1) in chronic hepatitis C, Journal of Hepatology 46
(4) (2007) 605–612. http://dx.doi.org/10.1016/j.jhep.2006.11.009 17196701.
[50] S. Sutti, M. Vidali, C. Mombello, M. Sartori, E. Albano, Conformational anti-
cytochrome P4502E1 (CYP2E1) auto-antibodies contribute to necro-in-
flammatory injury in chronic hepatitis C, Journal of Viral Hepatitis 17 (10)
(2010) 685–690. http://dx.doi.org/10.1111/j.1365-2893.2010.01359.x
20738774.
[51] M. Berenguer, What determines the natural history of recurrent hepatitis C
after liver transplantation? Journal of Hepatology 42 (4) (2005) 448–456. http:
//dx.doi.org/10.1016/j.jhep.2005.01.011 15763325.
[52] D. Vergani, G. Mieli-Vergani, Autoimmunity after liver transplantation, He-
patology 36 (2) (2002) 271–276. http://dx.doi.org/10.1053/jhep.2002.35339
12143033.
[53] C. Rigamonti, M. Vidali, M.F. Donato, S. Sutti, G. Occhino, A. Ivaldi, E. Arosio,
F. Agnelli, G. Rossi, M. Colombo, E. Albano, Serum autoantibodies against cy-
tochrome P450 2E1 (CYP2E1) predict severity of necroinflammation of re-
current hepatitis C, American Journal of Transplantation 9 (3) (2009) 601–609.
http://dx.doi.org/10.1111/j.1600-6143.2008.02520.x 19191768.
[54] M. Vidali, M. Hidestrand, E. Eliasson, E. Mottaran, E. Reale, R. Rolla, G. Occhino,
E. Albano, M. Ingelman-Sundberg, Use of molecular simulation for mapping
conformational CYP2E1 epitopes, Journal of Biological Chemistry 279 (49)
(2004) 50949–50955. http://dx.doi.org/10.1074/jbc.M407329200 15456790.
[55] S. Sutti, M. Vidali, C. Mombello, M. Sartori, M. Ingelman-Sundberg, E. Albano,
Breaking self-tolerance toward cytochrome P4502E1 (CYP2E1) in chronic
hepatitis C: possible role for molecular mimicry, Journal of Hepatology 53 (3)
(2010) 431–438. http://dx.doi.org/10.1016/j.jhep.2010.03.030 20576306.
[56] Y. Ma, M.G. Thomas, M. Okamoto, D.P. Bogdanos, S. Nagl, N. Kerkar, A.R. Lopes,
L. Muratori, M. Lenzi, F.B. Bianchi, G. Mieli-Vergani, D. Vergani, Key residues of
a major cytochrome P4502D6 epitope are located on the surface of the mo-
lecule, Journal of Immunology 169 (1) (2002) 277–285. http://dx.doi.org/
10.4049/jimmunol.169.1.277 12077255.
[57] V. Racanelli, B. Rehermann, The liver as an immunological organ, Hepatology
43 (2 Suppl. 1) (2006) S54–S62. http://dx.doi.org/10.1002/hep.21060
16447271.
[58] I.N. Crispe, Immune tolerance in liver disease, Hepatology (2014), http://dx.
doi.org/10.1002/hep.27254 24913836.
[59] F. Winau, C. Quack, A. Darmoise, S.H. Kaufmann, Starring stellate cells in liver
immunology, Current Opinion in Immunology 20 (1) (2008) 68–74. http://dx.
doi.org/10.1016/j.coi.2007.10.006 18068343.
[60] J. Herkel, B. Jagemann, C. Wiegard, J.F. Lazaro, S. Lueth, S. Kanzler, M. Blessing,
E. Schmitt, A.W. Lohse, MHC class II-expressing hepatocytes function as an-
tigen-presenting cells and activate specific CD4 T lymphocyutes, Hepatology
37 (5) (2003) 1079–1085. http://dx.doi.org/10.1053/jhep.2003.50191.
[61] F.N. Van Pelt, P. Straub, M.P. Manns, Molecular basis of drug-induced im-
munological liver injury, Seminars in Liver Disease 15 (3) (1995) 283–300.
http://dx.doi.org/10.1055/s-2007-1007281 7491507.
[62] J. Ehser, M. Holdener, S. Christen, M. Bayer, J.M. Pfeilschifter, E. Hintermann,
D. Bogdanos, U. Christen, Molecular mimicry rather than identity breaks T-cell
tolerance in the CYP2D6 mouse model for human autoimmune hepatitis,
J. Autoimmune 42 (2013) 39–49. http://dx.doi.org/10.1016/j.jaut.2012.11.001
23200317.
[63] J.M. Palmer, A.J. Robe, A.D. Burt, J.A. Kirby, D.E. Jones, Covalent modification as
a mechanism for the breakdown of immune tolerance to pyruvate dehy-
drogenase complex in the mouse, Hepatology 39 (6) (2004) 1583–1592. http:
//dx.doi.org/10.1002/hep.20248 15185299.
[64] A.J. Czaja, Drug-induced autoimmune-like hepatitis, Digestive Diseases and
Sciences 56 (4) (2011) 958–976. http://dx.doi.org/10.1007/s10620-011-1611-4
21327704.
[65] P. Neafsey, G. Ginsberg, D. Hattis, D.O. Johns, K.Z. Guyton, B. Sonawane, Ge-
netic polymorphism in CYP2E1: population distribution of CYP2E1 activity,
Journal of Toxicology and Environmental Health B Critical Reviews 12 (5–6)
(2009) 362–388. http://dx.doi.org/10.1080/10937400903158359 20183527.
S. Sutti et al. / Redox Biology 3 (2014) 72–7878[66] C. Münz, J.D. Lünemann, M.T. Getts, S.D. Miller, Antiviral immune responses:
triggers of or triggered by autoimmunity? Nature Reviews Immunology 9 (4)
(2009) 246–258. http://dx.doi.org/10.1038/nri2527 19319143.
[67] G. Marceau, P. Lapierre, K. Béland, H. Soudeyns, F. Alvarez, LKM1 auto-
antibodies in chronic hepatitis C infection: a case of molecular mimicry?
Hepatology 42 (3) (2005) 675–682. http://dx.doi.org/10.1002/hep.20816
16037945.
[68] A.R. Kammer, S.H. van der Burg, B. Grabscheid, I.P. Hunziker, K.
M. Kwappenberg, J. Reichen, C.J. Melief, Molecular mimicry of human cyto-
chrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition,
Journal of Experimental Medicine 190 (2) (1999) 169–176. http://dx.doi.org/
10.1084/jem.190.2.169 10432280.
[69] E.M. Shevach, R.A. DiPaolo, J. Andersson, D.M. Zhao, G.L. Stephens, A.
M. Thornton, The lifestyle of naturally occurring CD4þ CD25þ Foxp3þ reg-
ulatory T cells, Immunological Reviews 212 (2006) 60–73. http://dx.doi.org/
10.1111/j.0105-2896.2006.00415.x 16903906.
[70] D.A. Vignali, L.W. Collison, C.J. Workman, How regulatory T cells work, Nature
Reviews Immunology 8 (7) (2008) 523–532. http://dx.doi.org/10.1038/nri2343
18566595.
[71] M.S. Longhi, M.J. Hussain, W.W. Kwok, G. Mieli-Vergani, Y. Ma, D. Vergani,
Autoantigen-specific regulatory T cells, a potential tool for immune-tolerance
reconstitution in type-2 autoimmune hepatitis, Hepatology 53 (2) (2011)
536–547. http://dx.doi.org/10.1002/hep.24039.[72] L.S. Walker, Treg and CTLA-4: two intertwining pathways to immune toler-
ance, Journal of Autoimmunity 45 (2013) 49–57. http://dx.doi.org/10.1016/j.
jaut.2013.06.006 23849743.
[73] K.J. Scalapino, D.I. Daikh, CTLA-4: a key regulatory point in the control of
autoimmune disease, Immunological Reviews 223 (2008) 143–155. http://dx.
doi.org/10.1111/j.1600-065X.2008.00639.x 18613834.
[74] S.C. Gough, L.S. Walker, D.M. Sansom, CTLA4 gene polymorphism and auto-
immunity, Immunological Reviews 204 (2005) 102–115. http://dx.doi.org/
10.1111/j.0105-2896.2005.00249.x 15790353.
[75] J.M. Kim, J.P. Rasmussen, A.Y. Rudensky, Regulatory T cells prevent cata-
strophic autoimmunity throughout the lifespan of mice, Nature Immunology 8
(2) (2007) 191–197. http://dx.doi.org/10.1038/ni1428 17136045.
[76] E. Liaskou, G.M. Hirschfield, M.E. Gershwin, Mechanisms of tissue injury in
autoimmune liver diseases, Seminars in Immunopathology 36 (5) (2014)
553–568. http://dx.doi.org/10.1007/s00281-014-0439-3 25082647.
[77] N. Chalasani, J.C. Gorski, M.S. Asghar, A. Asghar, B. Foresman, S.D. Hall, D.
W. Crabb, Hepatic cytochrome P450 2E1 activity in nondiabetic patients with
nonalcoholic steatohepatitis, Hepatology 37 (3) (2003) 544–550. http://dx.doi.
org/10.1053/jhep.2003.50095 12601351.
[78] M.G. Emery, J.M. Fisher, J.Y. Chien, E.D. Kharasch, E.P. Dellinger, K.V. Kowdley,
K.E. Thummel, CYP2E1 activity before and after weight loss in morbidly obese
subjects with nonalcoholic fatty liver disease, Hepatology 38 (2) (2003)
428–435. http://dx.doi.org/10.1053/jhep.2003.50342 12883487.
